Abstract CT226: Crizotinib (C) in patients (pts) with solid tumors with MET amplification (amp) or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Document Type

Abstract

Publication Date

4-15-2023

Publication Title

Cancer Research

Keywords

oregon; chiles

Abstract

Background: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in pts with advanced cancers with specific genomic alterations. Results in a cohort of pts with solid tumors and MET amp or mut treated with C are reported.

Methods: Eligible pts had no standard treatment (tx) options, had measurable disease, ECOG performance status (PS) 0-2, and adequate organ function. Pts with non-small cell lung cancer were excluded. Genomic testing was performed in CLIA-certified, CAP-accredited site selected labs. Pts received C at 250 mg orally BID until disease progression. Low accruing histology-specific cohorts with MET amp or mut were collapsed into 1 histology-pooled cohort for analysis. Primary end point was disease control (DC) per investigator, defined as complete or partial response (PR) or stable disease (SD) of at least 16+ weeks (wks) duration (SD16+) per RECIST v1.1. The primary end point was summarized as a proportion and the hypothesized null DC rate of 15% was evaluated by a 1-sided exact binomial test with α= 0.10. Other end points were progression-free survival (PFS), overall survival (OS), duration of response and SD, and safety.

Results: 31 pts with solid tumors (12 tumor types) and MET mut only (n=10), amp only (n=19), or mut and amp (n=1) were enrolled; 1 pt with overexpression was ineligible. 3 additional pts were unevaluable for efficacy. Table shows demographics and outcomes. 2 PR (both esophageal adenocarcinoma with MET amp) and 4 SD16+ (2 renal cell carcinoma, 1 with mut, 1 with amp; colorectal with amp; small intestine with amp) were observed for DC rate of 21% (1-sided 90% CI: 12%, 100%) and objective response rate of 7% (95% CI: 1%, 24%). The null DC rate was not rejected. 5 pts had ≥1 grade 3 tx-related adverse or serious adverse event.

Conclusions: C did not meet prespecified criteria to declare a signal of activity in pts with solid tumors with MET amp or mut.

Clinical Institute

Cancer

Department

Earle A. Chiles Research Institute

Department

Oncology

Comments

Kathryn F. Mileham; Michael Rothe; Pam K. Mangat; Elizabeth Garrett-Mayer; Herbert L. Duvivier; Carmen J. Calfa; Carrie L. Dul; Alissa S. Marr; Eugene R. Ahn; Deepti Behl; Michael J. Hall; Inderjit Mehmi; Anu Gaba; Rom Leidner; Mark M. Zalupski; Gina N. Grantham; Abigail Gregory; Susan Halabi; Richard L. Schilsky

This document is currently not available here.


Share

COinS